These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27742788)

  • 1. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
    Maxwell JE; Sherman SK; Howe JR
    Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetics of neuroendocrine tumors.
    Öberg K
    Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A; Neuzillet C; Couvelard A; Serova M; de Gramont A; Hammel P; Raymond E; Faivre S
    Target Oncol; 2012 Sep; 7(3):173-81. PubMed ID: 22923165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
    Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.
    Capurso G; Archibugi L; Delle Fave G
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):594-601. PubMed ID: 25619712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent studies show promise for treating rare pancreatic tumors.
    Peres J
    J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
    Capozzi M; VON Arx C; DE Divitiis C; Ottaiano A; Tatangelo F; Romano GM; Tafuto S;
    Anticancer Res; 2016 Oct; 36(10):5025-5030. PubMed ID: 27798861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
    Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
    J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
    Barna ME; Uomo I; Pastorello M
    JOP; 2013 Jan; 14(1):102-4. PubMed ID: 23306347
    [No Abstract]   [Full Text] [Related]  

  • 13. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE; German MS; Yang K; Wang J; VanBrocklin H; Regan M; Shokat KM; Ducker GS; Kim GE; Hann B; Donner DB; Warren RS; Venook AP; Bergsland EK; Lee D; Wang Y; Nakakura EK
    Mol Cancer Ther; 2018 Dec; 17(12):2702-2709. PubMed ID: 30254185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
    Liakakos T; Roukos DH
    Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
    [No Abstract]   [Full Text] [Related]  

  • 15. Sunitinib in pancreatic neuroendocrine tumors.
    Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
    Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
    Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
    J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
    Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
    Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 20. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT; Delle Fave G
    N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.